State of Alaska Department of Revenue reduced its position in DaVita Inc. (NYSE:DVA – Free Report) by 4.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 5,144 shares of the company’s stock after selling 215 shares during the period. State of Alaska Department of Revenue’s holdings in DaVita were worth $769,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Exchange Traded Concepts LLC bought a new stake in shares of DaVita in the 3rd quarter worth $135,000. Vontobel Holding Ltd. increased its holdings in DaVita by 17.2% in the 3rd quarter. Vontobel Holding Ltd. now owns 2,243 shares of the company’s stock worth $368,000 after buying an additional 329 shares in the last quarter. Capital Investment Advisors LLC purchased a new position in DaVita in the 3rd quarter worth about $213,000. Blue Trust Inc. lifted its stake in DaVita by 56.4% during the 3rd quarter. Blue Trust Inc. now owns 330 shares of the company’s stock valued at $54,000 after acquiring an additional 119 shares during the period. Finally, Raymond James & Associates boosted its holdings in shares of DaVita by 93.6% during the 3rd quarter. Raymond James & Associates now owns 31,316 shares of the company’s stock valued at $5,134,000 after acquiring an additional 15,138 shares during the last quarter. 90.12% of the stock is owned by institutional investors.
DaVita Stock Down 11.4 %
DVA stock opened at $156.95 on Friday. The business’s 50-day moving average is $161.41 and its two-hundred day moving average is $157.37. The company has a market cap of $12.87 billion, a price-to-earnings ratio of 16.93, a P/E/G ratio of 0.84 and a beta of 0.94. DaVita Inc. has a fifty-two week low of $118.56 and a fifty-two week high of $179.60. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37.
Wall Street Analysts Forecast Growth
Separately, Barclays boosted their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $161.80.
Get Our Latest Stock Report on DaVita
DaVita Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
- Five stocks we like better than DaVita
- What to Know About Investing in Penny Stocks
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- What is the NASDAQ Stock Exchange?
- Up 50% in January, Twilio’s Pullback Is the Time to Buy
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.